134 related articles for article (PubMed ID: 35760337)
21. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
Narod SA; Boyd J
Curr Opin Obstet Gynecol; 2002 Feb; 14(1):19-26. PubMed ID: 11801872
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Clinical Outcomes of
Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
Le Page C; Rahimi K; Köbel M; Tonin PN; Meunier L; Portelance L; Bernard M; Nelson BH; Bernardini MQ; Bartlett JMS; Bachvarov D; Gotlieb WH; Gilks B; McAlpine JN; Nachtigal MW; Piché A; Watson PH; Vanderhyden B; Huntsman DG; Provencher DM; Mes-Masson AM
BMC Cancer; 2018 Mar; 18(1):347. PubMed ID: 29587661
[TBL] [Abstract][Full Text] [Related]
24. Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
Lavoro A; Scalisi A; Candido S; Zanghì GN; Rizzo R; Gattuso G; Caruso G; Libra M; Falzone L
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35383859
[TBL] [Abstract][Full Text] [Related]
25. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
26. Hereditary ovarian cancers: state of the art.
Toss A; Molinaro E; Sammarini M; Del Savio MC; Cortesi L; Facchinetti F; Grandi G
Minerva Med; 2019 Aug; 110(4):301-319. PubMed ID: 31081309
[TBL] [Abstract][Full Text] [Related]
27. [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
Badora A; Kaleta B; Nowara E; Sikora-Jopek M; Budryk M; Smok-Ragankiewicz A
Ginekol Pol; 2013 Oct; 84(10):892-6. PubMed ID: 24273914
[TBL] [Abstract][Full Text] [Related]
28. [Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers].
Zikán M
Klin Onkol; 2016; 29 Suppl 1():S22-30. PubMed ID: 26691939
[TBL] [Abstract][Full Text] [Related]
29. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.
Balkwill F; Bast RC; Berek J; Chenevix-Trench G; Gore M; Hamilton T; Jacobs I; Mills G; Souhami R; Urban N; Orsulic S; Smyth J
Eur J Cancer; 2003 Sep; 39(13):1818-27. PubMed ID: 12932658
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
Stefansson OA; Villanueva A; Vidal A; Martí L; Esteller M
Epigenetics; 2012 Nov; 7(11):1225-9. PubMed ID: 23069641
[TBL] [Abstract][Full Text] [Related]
31. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
[TBL] [Abstract][Full Text] [Related]
32.
Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
[TBL] [Abstract][Full Text] [Related]
33. Hereditary gynaecological malignancies: advances in screening and treatment.
Folkins AK; Longacre TA
Histopathology; 2013 Jan; 62(1):2-30. PubMed ID: 23240667
[TBL] [Abstract][Full Text] [Related]
34. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
[TBL] [Abstract][Full Text] [Related]
35. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
[TBL] [Abstract][Full Text] [Related]
36. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
[TBL] [Abstract][Full Text] [Related]
37. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
Liu G; Yang D; Sun Y; Shmulevich I; Xue F; Sood AK; Zhang W
Pharmacogenomics; 2012 Oct; 13(13):1523-35. PubMed ID: 23057551
[TBL] [Abstract][Full Text] [Related]
38. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
39. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
40. [Can new molecular profiles in epithelial ovarian cancer modify therapeutics?].
Lavoué V; Rousselin A; Delplanque S; Pinsard M; Henno S; Foucher F; Levêque J; de la Motte Rouge T
J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):107-112. PubMed ID: 28403964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
